Click image to view original image
Skype:kafenbiotech
WhatsApp:+8618011892373
www.kafenbiotech.com
1.Quick Details:
2.Product Description:
An aromatase inhibitor. Used as an antineoplastic raw materials.Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse after adjuvant therapy after menopause for women with advanced breast cancer.
Arimidex is the aromatase inhibitor of choice. Arimidex's mechanism of action - blocking conversion of aromatizable steroids to estrogen - is in contrast to the mechanism of action of anti-estrogens such as clomiphene (Clomid) (Nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others.
The drug is appropriately used when using substantial amounts of aromatizing steroids, or when one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex, and for this reason blood tests, or less preferably salivary tests, should be taken after the first week of use to determine if the dosing is correct.
3.Product Application:
The drug is appropriately used when using substantial amounts of aromatizing steroids, or when one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex, and for this reason blood tests, or less preferably salivary tests, should be taken after the first week of use to determine if the dosing is correct.
Three azole aromatase inhibitors are potent selective, it can inhibit the cytochrome P-450 dependent aromatase thereby blocking the biosynthesis of estrogen, but estrogen is the main factor that stimulates the growth of breast cancer cells.
The treatment of breast cancer, especially for those with adjuvant hormone therapy after menopause after recurrence of women with advanced breast cancer.
4.COA:
1.Quick Details:
| Product Name | Arimidex |
| Chemical Name | Anastrozole arimidex |
| CAS Number | 120511-73-4 |
| Molecular Formula | C17H19N5 |
| Molecular Weight | 293.37 |
| Melting Point | 81.0~84.0ºC |
| Assay | 99.5% |
| Appearance | White powder |
2.Product Description:
An aromatase inhibitor. Used as an antineoplastic raw materials.Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse after adjuvant therapy after menopause for women with advanced breast cancer.
Arimidex is the aromatase inhibitor of choice. Arimidex's mechanism of action - blocking conversion of aromatizable steroids to estrogen - is in contrast to the mechanism of action of anti-estrogens such as clomiphene (Clomid) (Nolvadex), which block estrogen receptors in some tissues, and activate estrogen receptors in others.
The drug is appropriately used when using substantial amounts of aromatizing steroids, or when one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex, and for this reason blood tests, or less preferably salivary tests, should be taken after the first week of use to determine if the dosing is correct.
3.Product Application:
The drug is appropriately used when using substantial amounts of aromatizing steroids, or when one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex, and for this reason blood tests, or less preferably salivary tests, should be taken after the first week of use to determine if the dosing is correct.
Three azole aromatase inhibitors are potent selective, it can inhibit the cytochrome P-450 dependent aromatase thereby blocking the biosynthesis of estrogen, but estrogen is the main factor that stimulates the growth of breast cancer cells.
The treatment of breast cancer, especially for those with adjuvant hormone therapy after menopause after recurrence of women with advanced breast cancer.
4.COA:
| Items | Standard | Results |
| Description | White crystalline powder | Complies |
| Identification | IR HPLC Reactive |
Conform with standard IR Conform with standard HPLC Conform |
| Solubility | Freely soluble in methanol,acetone,ethanol and tetrahydrofuran. And very soluble in acetonitrile |
Complies |
| Total Impurity | max.0.5% | 0.18% |
| Total Unspecified Impurity | max. 0.2% | 0.08% |
| Individual unspecified impurlty |
max. 0.1% | 0.05% |
| Related compound B | max. 0.2% | 0.07% |
| Related compound C | max. 0.2% | 0.04% |
| Related compound D | max. 0.1% | 0.05% |
| Related compound E | max. 0.1% | 0.06% |
| Limit of cyclohexane | max. 0.08% | ND |
| Limit of ethylacetate | max. 0.1% | 0.07% |
| Melting point | 81.0~84.0 | 82.5~83.2 |
| Water | max. 0.3% | 0.21% |
| Residue on ignition | max. 0.1% | 0.07% |
| Heavy metals | max.0.001% | Complies |
| Assay(HPLC) | 98.0%~102.0% | 99.8% |
